Nxstage Medical (NXTM) Tops Q1 EPS by 3c; Sees FY16 Results at High-End of Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
NxStage Reports First Quarter Financial Results
May 4, 2016 8:05 AM EDTLAWRENCE, Mass., May 4, 2016 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today reported first quarter financial results above the top end of its guidance.
Total revenue for the first quarter of 2016 increased 12 percent to $89.2 million, compared with revenue of $79.5 million for the first quarter of 2015. The Company's revenue guidance range for the first quarter was $87 to $89 million.
The... More
